The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
Bolli will lead worldwide business development for the company’s Contract Development and Manufacturing Organisation (CDMO) services
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Subscribe To Our Newsletter & Stay Updated
